RxDoctor Payments Data

Robert Goldberg, MD

Pulmonary Disease · Mission Viejo, CANPI 1609920008

Payments from drug & device makers

$96,555in general payments, 2019–2025

Across 296 payments — averaging $326.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$75K
  • Johnson & Johnson$9K
  • Intuitive Surgical$8K
  • Medical Device Business Services, Inc.$1K
  • GSK$630
  • Boehringer Ingelheim$390
  • plus $3K from 36 others

What the payments were for

  • Consulting fees$42,24744%
  • Speaking & faculty fees$29,85931%
  • Travel & lodging$10,45311%
  • Food & beverage$8,4789%
  • Education$5,5176%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$96,555 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$278,484
Medicare patients
499
Services billed
1,989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor12$168,036
Trelegy ElliptaFluticasone/Umeclidin/Vilanter102$73,819
Ambrisentan13$40,818
Spiriva RespimatTiotropium Bromide53$30,919
Stiolto RespimatTiotropium Br/Olodaterol Hcl61$30,256
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$25,558
EliquisApixaban29$25,445
XareltoRivaroxaban18$24,019
Breo ElliptaFluticasone/Vilanterol50$22,395
Incruse ElliptaUmeclidinium Bromide52$21,151
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$18,720
Advair HfaFluticasone Propion/Salmeterol29$12,210
SymbicortBudesonide/Formoterol Fumarate15$8,004
Arnuity ElliptaFluticasone Furoate25$5,545
DuleraMometasone/Formoterol11$5,192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCProlastin C$17$168,03612 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$630$141,630255 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$390$61,175114 claims
AstraZenecaBreztri Aerosphere, Symbicort$66$33,56242 claims
PfizerEliquis$79$25,44529 claims
Johnson & JohnsonXarelto$8,986$24,01918 claims
MerckDulera$64$5,19211 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$15$4,71817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →